Where others have failed will Atl1102 succeed ?, page-583

@waynesworld

Is there ever

Funny that us mere retail mortals have been discussing potential movements with Sarepta ever since the Phase 2B results landed.

Join the dots...

The Goolsbee and Dr Price connection to Sarepta Board.

Prof Voit and his part ownership of the micro-dystrophin patent used by Sarepta.

PPMD influence on Pharma roadmap and FDA decision making.

Sarepta's desperate need for efficacy data for Exondys51 - read combination trial with ATL1102.

...and now - Sarepta's dismal results with Gene Therapy.

In March investor webinar, the Diamond threw shade at Sarepta's program...that after all these years Sarepta has not proven efficacy for Exondys.

This week Mark Diamond is "liking" Sarepta's LinkedIn feed.

So...Sarepta can have US rights for $300m upfront and $1 billion in Biobucks

ANP can then move on with EMA trial.

Let's see how it goes.
.